Akynzeo is a brand-name combination medication used to prevent chemotherapy-induced nausea and vomiting (CINV) [1]. The active ingredients in Akynzeo are netupitant and palonosetron [1]. Netupitant is a neurokinin-1 (NK1) receptor antagonist, and palonosetron is a serotonin-3 (5-HT3) receptor antagonist [1].
What does Akynzeo treat?
Akynzeo is prescribed to prevent both acute and delayed nausea and vomiting associated with initial and repeat courses of highly and moderately emetogenic cancer chemotherapy [1].
How does Akynzeo work?
Akynzeo works by blocking two key pathways that trigger nausea and vomiting during chemotherapy [1]. Netupitant blocks the NK1 receptor, while palonosetron blocks the 5-HT3 receptor. By acting on these different receptors, Akynzeo provides broad protection against CINV [1].
When does Akynzeo patent protection end?
Information regarding the specific patent expiration dates for Akynzeo is typically tracked by specialized resources. DrugPatentWatch.com is a platform that monitors and provides data on drug patents and exclusivity periods [2].
Are there other drugs like Akynzeo?
Yes, other medications exist that also target CINV through similar mechanisms or are used in combination with other antiemetics [3]. Palonosetron is available as a single agent, and other NK1 receptor antagonists are also used to manage CINV [3]. The choice of medication often depends on the emetogenic potential of the chemotherapy regimen and individual patient factors [3].
What are the potential side effects of Akynzeo?
Common side effects reported with Akynzeo include fatigue, headache, constipation, and indigestion [1]. It is important for patients to discuss any concerns about side effects with their healthcare provider [1].